Related Experiment Video

Updated: Dec 21, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.4K

Good prognosis or poor prognosis, dose-intensive or less intensive: who decides for adults with T-lymphoblastic

Ken H Young1

  • 1Duke University Medical Center, Division of Hematopathology and Department of Pathology, Duke University Cancer Institute, Durham, NC, USA. ken.young@duke.edu.

Leukemia
|May 14, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.5K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.1K

Related Experiment Videos

Last Updated: Dec 21, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.4K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.5K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.1K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Lineage Commitment01:21

Lineage Commitment

3.9K
Commitment is the  process whereby stem cells:
3.9K

Articles linked to this work by shared authors, journal, and citation graph.

Grading of Castleman Disease Histopathology with an Attention-Based Multiple Instance Learning Model.

Diagnostics (Basel, Switzerland)·2026

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026

Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Leukemia·2026

Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.

Blood advances·2025

Correction: Targeting RAB7 in human B lymphoma by a small molecule inhibitor arrests tumor cell growth.

Frontiers in oncology·2025

Targeting RAB7 in human B lymphoma by a small molecule inhibitor arrests tumor cell growth.

Frontiers in oncology·2025

Mitochondria transfer via tunneling nanotubes drives macrophage immunosuppression and metabolic reprogramming in pediatric AML.

Leukemia·2026

Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study.

Leukemia·2026

RUNX1 aberrations in blast-phase chronic myeloid leukaemia induce the RNA-binding protein SPATS2L, which promotes growth, survival and stress granule assembly.

Leukemia·2026

Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurin.

Leukemia·2026

Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia.

Leukemia·2026

Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy.

Leukemia·2026

Proton Radiotherapy Decreases Incidence of Radiation-Induced Second Malignant Neoplasms Compared to Photon Radiotherapy in Patients With Retinoblastoma.

Pediatric blood & cancer·2026

Utilization of 68Ga-FAPI PET/CT improves the gross tumor volume delineation in nasopharyngeal carcinoma within a safe radiation dose to organs at risk.

Quantitative imaging in medicine and surgery·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us